Table 1.

Table summarizing key findings from recent studies.

Study	Key findings
ODYSSEY	The Dolutegravir 50 mg film-coated tablet is safe and efficacious with similar bioavailability to adults when used in children above 20 kg than lower dose formulations.
IMPAACT P1093	Dolutegravir was well tolerated and safe among adolescents through 153 weeks of follow-up.
LOLIPOP	Fixed-dose combination granules of abacavir, lamivudine, and Lopinavir/ritonavir (4 in 1 formulation called quadrimmune) is safe and effective in achieving or maintaining viral suppression, produces good drug exposure, and is more acceptable than Lopinavir/ritonavir pellets or other previous formulations.
GS-US-292-0106	Once daily single-tablet coformulation of 150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide maintained viral suppression and was safe in 24 weeks of follow-up among children 6–11 years.
GS-9883/F/TAF	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg was safe, acceptable, and maintained viral suppression through 96 weeks of follow-up among children and adolescents aged 6–18 years (⩾25 kg).
REALITY	An enhanced prophylaxis package (12 weeks of fluconazole 100 mg daily), 12 weeks of fixed-dose combination of co-trimoxazole, isoniazid, and pyridoxine as a once daily tablet, 5 days of azithromycin and a single dose of albendazole enhanced prophylaxis package reduced mortality by 27% over 24 weeks compared to standard of care (co-trimoxazole) according to national guidelines. Ready-to-use supplementary food did not reduce early mortality.
SMILE	Once daily integrase inhibitors plus darunavir/ritonavir was noninferior to standard of care triple ART and was equally safe among virologically children aged 6–18 years.

ART, antiretroviral therapy.